$36.5 Billion is the total value of VIKING GLOBAL INVESTORS LP's 96 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BRIDGEBIO PHARMA INC | $1,247,726,000 | -23.1% | 26,620,991 | 0.0% | 3.42% | -30.4% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $1,019,486,000 | -16.8% | 29,993,708 | 0.0% | 2.80% | -24.8% | |
| APG | API GROUP CORP | $678,333,000 | -2.6% | 33,333,333 | 0.0% | 1.86% | -11.9% | |
| INBX | INHIBRX INC | $176,738,000 | +21.0% | 5,305,866 | 0.0% | 0.48% | +9.5% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $106,206,000 | +12.0% | 3,937,914 | 0.0% | 0.29% | +1.0% | |
| PMVP | PMV PHARMACEUTICALS INC | $53,350,000 | -12.8% | 1,790,284 | 0.0% | 0.15% | -21.1% | |
| EWTX | EDGEWISE THERAPEUTICS INC | $45,272,000 | -22.2% | 2,727,249 | 0.0% | 0.12% | -29.5% | |
| TALS | TALARIS THERAPEUTICS INC | $44,607,000 | -7.7% | 3,289,617 | 0.0% | 0.12% | -17.0% | |
| KNTE | KINNATE BIOPHARMA INC | $41,907,000 | -1.1% | 1,820,462 | 0.0% | 0.12% | -10.2% | |
| PHVS | PHARVARIS N V | $41,254,000 | -5.1% | 2,391,517 | 0.0% | 0.11% | -14.4% | |
| EM | SMART SH GLOBAL LTDads | $1,570,000 | -45.0% | 470,000 | 0.0% | 0.00% | -55.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VISA INC | 36 | Q3 2023 | 7.0% |
| AMAZON COM INC | 34 | Q3 2023 | 10.6% |
| META PLATFORMS INC | 34 | Q3 2023 | 10.4% |
| MICROSOFT CORP | 30 | Q3 2023 | 9.1% |
| THERMO FISHER SCIENTIFIC INC | 29 | Q3 2023 | 5.4% |
| NETFLIX INC | 26 | Q2 2023 | 6.0% |
| MASTERCARD INCORPORATED | 25 | Q3 2023 | 3.9% |
| ELEVANCE HEALTH INC | 24 | Q2 2023 | 10.2% |
| ALPHABET INC | 22 | Q2 2021 | 9.3% |
| UNITEDHEALTH GROUP INC | 22 | Q3 2023 | 5.3% |
View VIKING GLOBAL INVESTORS LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Celldex Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Coupa Software IncSold out | February 14, 2023 | 0 | 0.0% |
| FIGS, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Guardant Health, Inc. | February 14, 2023 | 4,107,644 | 4.0% |
| Orion Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| PROCEPT BioRobotics CorpSold out | February 14, 2023 | 0 | 0.0% |
| Frazier Lifesciences Acquisition CorpSold out | November 25, 2022 | 0 | 0.0% |
| Cazoo Group Ltd | November 10, 2022 | 60,000,000 | 7.3% |
| AbCellera Biologics Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View VIKING GLOBAL INVESTORS LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-20 |
| SC 13G/A | 2024-03-20 |
| 4 | 2024-03-07 |
| 4 | 2024-03-07 |
| 4 | 2024-03-01 |
| 4 | 2024-03-01 |
| SC 13G/A | 2024-03-01 |
| 4 | 2024-02-28 |
| 4 | 2024-02-28 |
| SC 13G/A | 2024-02-28 |
View VIKING GLOBAL INVESTORS LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.